NCT03387605View on ClinicalTrials.gov

Effect of Ivabradine in Stage D HF/Cardiogenic Shock Patients on Dobutamine

PHASE4UnknownINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 15, 2018

Primary Completion Date

January 31, 2020

Study Completion Date

June 30, 2020

Conditions
Heart FailureCardiogenic ShockTachycardia
Interventions
DRUG

Ivabradine

ivabradine or placebo given orally 2 times daily for 72 hours

DRUG

Placebo

matching placebo given 2 times daily for 72 hours

Trial Locations (1)

60153

RECRUITING

Loyola University Medical Center, Maywood

Sponsors

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

Loyola University

OTHER

NCT03387605 - Effect of Ivabradine in Stage D HF/Cardiogenic Shock Patients on Dobutamine | Biotech Hunter | Biotech Hunter